Lazertinib and its Impurities

Lazertinib, brand name - Lazcluze is a third-generation EGFR tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Reference standards of Lazertinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

Displaying 9 results for Lazertinib Impurities
Drug Reference Standards & Impurity Synthesis in India
PA 12 2200000

Lazertinib

Lazertinib


  • Catalogue No.:PA 12 2200000

  • CAS :

    1903008-80-9

  • Molecular Formula : C30H34N8O3

  • Molecular Weight : 554.66

Drug Reference Standards & Impurity Synthesis in India
PA 12 2201000

4-(2-Acrylamido-4-((4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-5-methoxyphenyl)morpholine 4-oxide

4-(2-Acrylamido-4-((4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-5-methoxyphenyl)morpholine 4-oxide


  • Catalogue No.:PA 12 2201000

  • CAS :

    NA

  • Molecular Formula : C30H34N8O4

  • Molecular Weight : 570.65

Drug Reference Standards & Impurity Synthesis in India
PA 12 2201001

N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-hydroxy-2-morpholinophenyl)acrylamide

N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-hydroxy-2-morpholinophenyl)acrylamide


  • Catalogue No.:PA 12 2201001

  • CAS :

    NA

  • Molecular Formula : C29H32N8O3

  • Molecular Weight : 540.63

Drug Reference Standards & Impurity Synthesis in India
PA 12 2201002

N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)-4-hydroxybutanamide

N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)-4-hydroxybutanamide


  • Catalogue No.:PA 12 2201002

  • CAS :

    NA

  • Molecular Formula : C31H38N8O4

  • Molecular Weight : 586.7

Drug Reference Standards & Impurity Synthesis in India
PA 12 2201003

N-(4-Methoxy-5-((4-(4-((methyl(nitroso)amino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-2-morpholinophenyl)acrylamide

N-(4-Methoxy-5-((4-(4-((methyl(nitroso)amino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-2-morpholinophenyl)acrylamide


  • Catalogue No.:PA 12 2201003

  • CAS :

    NA

  • Molecular Formula : C29H31N9O4

  • Molecular Weight : 569.63

Drug Reference Standards & Impurity Synthesis in India
PA 12 2201004

N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)(nitroso)amino)-4-methoxy-2-morpholinophenyl)acrylamide

N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)(nitroso)amino)-4-methoxy-2-morpholinophenyl)acrylamide


  • Catalogue No.:PA 12 2201004

  • CAS :

    NA

  • Molecular Formula : C30H33N9O4

  • Molecular Weight : 583.65

Drug Reference Standards & Impurity Synthesis in India
PA STI 090080

Lazertinib D9

Lazertinib D9


  • Catalogue No.:PA STI 090080

  • CAS :

    2288768-79-4

  • Molecular Formula : C30H25D9N8O3

  • Molecular Weight : 563.71

Drug Reference Standards & Impurity Synthesis in India
PA 12 2201005

3-Chloro-N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)propanamide

3-Chloro-N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)propanamide


  • Catalogue No.:PA 12 2201005

  • CAS :

    NA

  • Molecular Formula : C30H35ClN8O3

  • Molecular Weight : 591.11

Drug Reference Standards & Impurity Synthesis in India
PA 12 2201007

1-(2-((2-Methoxy-4-morpholino-5-nitrophenyl)amino)pyrimidin-4-yl)-5-phenyl-1H-pyrazole-4-carbaldehyde

1-(2-((2-Methoxy-4-morpholino-5-nitrophenyl)amino)pyrimidin-4-yl)-5-phenyl-1H-pyrazole-4-carbaldehyde


  • Catalogue No.:PA 12 2201007

  • CAS :

    NA

  • Molecular Formula : C25H23N7O5

  • Molecular Weight : 501.5